Reyataz is an anti-HIV drug for the HIV-positive patients that falls under Protease Inhibitors (PIs) category of the HIV medicines. Manufactured by Bristol-Myers Squibb, Reyataz was approved for the treatment of HIV patients by the U.S. Food and Drug Administration (FDA) in 2003.
Reyataz can be taken by both of the HIV positive patients, who have not taken anti-HIV drugs in the past, as well as those who have already taken such drugs earlier. Reyataz prevents T-cells infected by HIV from producing new virus. In this way, the drug is being able to reduce the amount of virus in the human body.
Reyataz must be taken in combination with at least two other anti-HIV drugs. Those who are starting anti-HIV drugs should take 400 mg of Reyataz in the form of two 200 mg capsules taken once in a day. Though the frequently prescribed dose is two 150 mg capsules of Reyataz along with a single 100 mg Norvir capsule, both taken once a day. Norvir is used to boost Reyataz levels in the bloodstream, to make it more effective against HIV. Those people who have used anti-HIV drugs earlier, can also maintain the second option. Reyataz should be taken with food, preferably with a complete nutritious meal, to ensure its absorption into the bloodstream.
Reyataz can interact with other medicines. Therefore while consulting your physician, tell about all the medicines you are taking. There are a few medicines that can`t be taken while taking Reyataz. Reyataz is also not approved for use for the HIV-positive children.
There might be some side effects of using Reyataz. Reyataz can increase bilirubin levels, which can cause the skin, nails and the whites of the eyes to appear yellowish. It can also cause liver damage. There also found some instances of developing painful kidney stones while taking Reyataz. Change in the heartbeats can also be experienced. It also can be seen symptoms like headaches, pain in the arms and legs, nausea, diarrhea, abdominal discomfort while taking Reyataz.
For more information on HIV/AIDS Drugs, please go through the website sitagita.